SCHEMBL4463700

SCHEMBL4463700

CN1C(=O)c2ccccc2C(C(=O)O)C1c1ccc(OCc2ccccc2)c(OCc2ccccc2)c1

nearest known ligand 0.65

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.65
POLB P06746 1/20 0.65
SMN1; SMN2 Q16637 1/20 0.65
HTT P42858 3/20 0.63
FFAR1 O14842 3/20 0.60
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
KDM4E B2RXH2 2/20 0.56
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56
MAPT P10636 3/20 0.56
GAA P10253 1/20 0.56
STING1 Q86WV6 1/20 0.54
HSD17B10 Q99714 3/20 0.54
TSHR P16473 1/20 0.52
GLA P06280 1/20 0.52
CASP1 P29466 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
LMNA P02545 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4463694 1.00 ALDH1A1 (0.65) ALDH1A1POLBSMN1; SMN2HTTFFAR1
SCHEMBL4462345 0.88 TSHR (0.63) ALDH1A1POLBSMN1; SMN2HTTMEN1
SCHEMBL4462343 0.88 TSHR (0.63) ALDH1A1POLBSMN1; SMN2HTTMEN1
SCHEMBL4456634 0.77 ALDH1A1 (0.71) ALDH1A1POLBSMN1; SMN2HTTFFAR1
SCHEMBL4456630 0.77 ALDH1A1 (0.71) ALDH1A1POLBSMN1; SMN2HTTFFAR1
SCHEMBL8782399 0.73 FFAR1 (0.70) ALDH1A1POLBSMN1; SMN2HTTFFAR1
SCHEMBL6410233 0.71 FFAR1 (0.61) ALDH1A1POLBSMN1; SMN2HTTFFAR1
SCHEMBL6410237 0.71 FFAR1 (0.61) ALDH1A1POLBSMN1; SMN2HTTFFAR1
SCHEMBL12185528 0.69 HTT (0.48) ALDH1A1POLBSMN1; SMN2HTTFFAR1
SCHEMBL9434336 0.68 PDE4B (0.45) ALDH1A1CYP1A2MAPTHSD17B10LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2050452-A1 indenoisoquinolines as topoisomerase inhibitors I useful as antineoplastic agents Purdue Research Foundation (US) 2009-04-22 EP disclosed
US-6509344-B1 A method for treating a patient having cancer, said method comprising the step of administering to the patient an effective amount of a compound according to claim 1, whereupon said patient is treated for cancer, and wherein the cancer is THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES 2003-01-21 US disclosed